Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 10;12:1018285. doi: 10.3389/fonc.2022.1018285

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Shen, Li, Zhang, Zhang, Wu, Da, Yang, Wang, Zhang, Qie, Zhao, Lin, Huang, Zhou and Hu

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

The ceRNA-associated gene signature is an important indicator of immune cell infiltration and immunotherapeutic effect. (A) The immune cell infiltration difference from 7 immune-infiltration algorithm in high-risk groups compared to low-risk groups. (B) The association between the risk score and immunotherapy outcome by wilcox test. (C) Correlations among the riskscore group and immunotherapy outcome variables. (D) Using TIDE algorithm analysis and the expression of partial immune checkpoint genes, immune checkpoint blockade therapy response based on riskscore was predicted. (E, F) Spearman association analysis between riskscore and immune cell infiltration was implemented. ceRNA, competing endogenous RNA; TIDE, tumor immune dysfunction and exclusion. *P < 0.05, **P < 0.01 and ***P < 0.001.